恩格列净联合二甲双胍、阿卡波糖治疗2型糖尿病合并射血分数降低型心力衰竭的临床效果及对心功能、体重的影响分析  

Clinical Effect of Englaglizin Combined with Metformin and Acarbose in the Treatment of Type 2 Diabetes Mellitus Complicated with Heart Failure and Influence on Heart Function and Body Weight

作　　者：赵雪华 姚月彬 ZHAO Xuehua;YAO Yuebin(Department of Pharmacy,Zhangzhou Affiliated Hospital of Fujian Medical University,Zhangzhou,Fujian 363000,China)

机构地区：[1]福建医科大学附属漳州市医院药学部,福建漳州363000

出　　处：《中国医药指南》2025年第10期74-76,共3页Guide of China Medicine

摘　　要：目的浅析恩格列净联合二甲双胍、阿卡波糖治疗2型糖尿病(T2DM)合并射血分数降低型心力衰竭(HFrEF)的临床效果及对心功能、体重的影响。方法选取福建医科大学附属漳州市医院2023年1月至2024年3月90例T2DM+HFrEF患者,按照随机数字表法分为对照组(45例,服用二甲双胍+阿卡波糖);观察组(45例,服用恩格列净+二甲双胍+阿卡波糖)。比较组间血糖、心功能、体重指数(BMI)、总有效率、用药不良反应和半年期心血管不良事件差异。结果观察组用药后血糖指标均低于对照组(均P<0.05);用药后观察组左心室射血分数高于对照组,左心室舒张末期内径、N端B型利钠肽原低于对照组(P<0.05);与对照组相比观察组BMI更低(P<0.05);两组治疗总有效率差异无统计学意义(P<0.05);观察组(6.67%)不良反应发生率低于对照组(8.89%)(P<0.05);两组半年期内,均未出现心血管不良事件。结论T2DM+HFrEF群体选择恩格列净+二甲双胍+阿卡波糖用药方案,能够发挥良好的针对性疗效,且安全性理想。Objective To analyze the clinical effect of englaglizin combined with metformin and acarbose in the treatment of type 2 diabetes mellitus(T2DM)with reduced ejection fraction heart failure(HFrEF)and its influence on cardiac function and body weight.Methods A total of 90 T2DM+HFrEF patients from Zhangzhou Hospital Affiliated to Fujian Medical University from January 2023 to March 2024 were selected and divided into a control group(45 patients receiving metformin+acarbose)according to random number table method.Observation group(45 cases,taking englaglizin+metformin+acarbose).Blood glucose,heart function,body mass index(BMI),total response rate,adverse drug reactions and half-year cardiovascular adverse events were compared between groups.Results Blood glucose indexes in observation group were lower than those in control group(All P<0.05).After treatment,the left ventricular ejection fraction in observation group was higher than that in control group,the left ventricular end-diastolic diameter and N-terminal B-type natriuretic peptide in observation group were lower than that in control group(P<0.05).The BMI of observation group was lower than that of control group(P<0.05).There was no significant difference in the total effective rate between the two groups(P<0.05).The incidence of adverse reactions in observation group(6.67%)was lower than that in control group(8.89%)(P<0.05).No adverse cardiovascular events occurred in both groups within half a year.Conclusions In T2DM+HFrEF group,the regimen of englaglizin+metformin+acarbose can play a good targeted therapeutic effect with ideal safety.

关 键 词：恩格列净 射血分数降低型心力衰竭 2型糖尿病 二甲双胍 

分 类 号：R587.1[医药卫生—内分泌] R541.6[医药卫生—内科学]